immatics biotechnologies ... (IMTXW)
0.03
-0.02 (-40.00%)
At close: Jan 14, 2025, 3:58 PM
0.05
60.00%
After-hours Jan 14, 2025, 07:49 PM EST
undefined% (undefined)
| Bid | 0.04 |
| Market Cap | 460.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.06 |
| Volume | 51,484 |
| Avg. Volume (20D) | 0 |
| Open | 0.05 |
| Previous Close | 0.05 |
| Day's Range | 0.03 - 0.06 |
| 52-Week Range | 0.03 - 0.06 |
| Beta | undefined |
About IMTXW
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 2, 2020
Employees 542
Stock Exchange NASDAQ
Ticker Symbol IMTXW
Website https://www.immatics.com